Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Preliminary Safety and Efficacy of RRG001 After Vitrectomy in Subjects With Proliferative Diabetic Retinopathy (PDR)
Sponsor: Li Xiaorong
Summary
This study aims to slow down disease progression, reduce postoperative complications and decrease retreatment frequency in subjects with proliferative diabetic retinopathy (PDR) by administering a single subretinal injection of RRG001 gene therapy after vitrectomy.
Official title: An Exploratory ITT(Investigator Initiated Study) Study to Evaluate the Preliminary Safety and Efficacy of Single Subretinal Injection of RRG001 at the End of or After Vitrectomy in Subjects With PDR
Key Details
Gender
All
Age Range
20 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
6
Start Date
2023-12-20
Completion Date
2028-12-31
Last Updated
2024-05-14
Healthy Volunteers
No
Conditions
Interventions
RRG001
Administered by subretinal injection. Dosage form: injection.
Locations (1)
Tianjin medical university eye hospital
Tianjin, China